BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 21, 2020
View Archived Issues
Benzoxazole analogues capable of reducing ChemR23 expression on monkey pDCs in vivo
Read More
ImmTAV molecules redirect T cells to lyse HBV DNA-integrated and virally infected cells in vitro
Read More
New phase II trial opens in France to study XAV-19 in COVID-19-induced moderate pneumonia
Read More
Athira opens enrollment in phase II trial of ATH-1017 for mild to moderate Alzheimer's
Read More
First-in-human study of progerinin
Read More
Discovery of novel potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors
Read More
Inhibition of alpha-KG-producing enzymes is therapeutic in diffuse intrinsic pontine glioma models
Read More
Novel FARS2 gene mutation causes spastic paraplegia 77
Read More
Tissue-specific p53 effects could aid drug development
Read More
Merck KGaA divulges PTPN11 inhibitors
Read More
Chinese researchers disclose ENPP2 inhibitors
Read More
Sunshine Lake Pharma patent reveals influenza virus replication inhibitors
Read More
1st Bio Therapeutics identifies ABL1 inhibitors
Read More
ADC Therapeutics starts enrollment in phase III study of loncastuximab tesirine in DLBCL
Read More
Optikira synthesizes new ERN1 inhibitors
Read More
Phase I/IIa data published for BIVV-001 in patients with hemophilia A
Read More
Ascletis begins phase I study of ASC-41 in healthy subjects
Read More
Akeso begins first-in-human study of COVID-19 treatment candidate AK-119
Read More
CIP2A as new diagnostic biomarker in Parkinson's disease
Read More
SAGE-718 studied in phase II for Parkinson's disease mild cognitive impairment
Read More
New antibody-mediated multiple sclerosis model developed
Read More
Confirmatory phase III trial of Pacev in urothelial cancer meets primary endpoint of OS
Read More
Shanghai Henlius Biotech begins phase I study with pertuzumab biosimilar HLX-11
Read More
APPA enters phase II trial for osteoarthritis
Read More